FDA Set Low Standards for Nicotine Product Approval

Aug.12.2022
FDA Set Low Standards for Nicotine Product Approval
FDA sets low review standards for tobacco companies in determining the safety of nicotine products.

I'm sorry, but "smolaw11" is not a phrase or sentence that requires translation as it is not written in any language. It appears to be a username or a code. Please provide the correct text for me to translate to standard journalistic English.


In an article for Filter, Alex Norcia explained that the US Food and Drug Administration (FDA) has set a lower standard for review of nicotine products in its Center for Tobacco Products (CTP) to determine their suitability for preserving public health than for companies submitting tobacco product applications before they go to market.


Filter has cited documents obtained through the Freedom of Information Act, which describe procedures such as batching and bracketing that allow CTP to apply conclusions to product categories rather than individual evaluations. According to Alex Norcia, "Despite the extremely burdensome bureaucratic demands placed on applicants, the agency is pleased to have found ways to complete its paperwork.


It is evident that the FDA allows itself to take effective shortcuts, but it denies applicants," said Clive Bates, Director of The Counterfactual, in an interview with Filter Magazine.


The issue at hand is that the FDA's extensive process is a considerable waste of time and resources for applicants, but ultimately, it is something that the FDA evaluators cannot manage. Without this shortcut, the PMTA process would become a nightmare for human resources. Therefore, the FDA allows itself to achieve the efficiency it should provide to applicants by blending and packaging thousands of almost identical products.


Statement:


This article is compiled from third-party information and is intended for industry-related exchanges and learning.


This article does not represent the viewpoints of 2FIRSTS and we cannot confirm the authenticity or accuracy of its content. The translation of this article is only for industry-related research and exchange.


Due to limitations in translation proficiency, the translated article may not fully reflect the original text. Please refer to the original text for accuracy.


2FIRSTS maintains full alignment with the Chinese government on any statements and positions related to domestic, Hong Kong, Macau, Taiwan, and foreign affairs.


The copyright of compiled information belongs to the original media and author. If there is any infringement, please contact us for removal.


This document has been generated through artificial intelligence translation and is provided solely for the purposes of industry discourse and learning. Please note that the intellectual property rights of the content belong to the original media source or author. Owing to certain limitations in the translation process, there may be discrepancies between the translated text and the original content. We recommend referring to the original source for complete accuracy. In case of any inaccuracies, we invite you to reach out to us with corrections. If you believe any content has infringed upon your rights, please contact us immediately for its removal.

Special Report|FDA Revises Device Name in Glas Vape Authorization; Company Signals Optimism on Menthol, Flavored Pods
Special Report|FDA Revises Device Name in Glas Vape Authorization; Company Signals Optimism on Menthol, Flavored Pods
The FDA updated public records on the PMTA authorization of a Glas vape product, renaming “Glas G Device” to “Glas G² Device” and releasing the order letter detailing scientific review and marketing restrictions. Company disclosures suggest the platform may include age-verification technology. If confirmed, Glas G² could be the first vape with device-level age verification to receive an FDA MGO. Glas executives also said menthol and other flavored pods could gain authorization in the future.
Special Report
Mar.14
BAT France Confirms Full Compliance as France Implements Nicotine Pouch Ban on April 1from April 2026
BAT France Confirms Full Compliance as France Implements Nicotine Pouch Ban on April 1from April 2026
BAT France said that, under the decree of September 5, 2025 that entered into force on April 1, 2026, it has stopped commercialising its nicotine pouch products in France from that date.
Apr.03 by 2FIRSTS.ai
Spain’s PSOE files motion to curb vaping and nicotine pouches, restricting sales channels and banning online sales
Spain’s PSOE files motion to curb vaping and nicotine pouches, restricting sales channels and banning online sales
Spain’s Socialist Party (PSOE) has registered a non-legislative motion (PNL) in Congress seeking to curb the use of vapes and nicotine pouches by restricting sales to authorised channels and banning sales online and in non-specialist shops. The proposal says the current “lack of control” in commercialisation facilitates tax evasion and breaches existing health and environmental rules.
Mar.03 by 2FIRSTS.ai
Smoore International Reports 2025 Revenue of RMB 14.256 Billion, Up 20.8%
Smoore International Reports 2025 Revenue of RMB 14.256 Billion, Up 20.8%
On March 17, Smoore International Holdings Limited released its annual results for the year ended December 31, 2025. Revenue reached RMB 14.256 billion, up 20.8% year on year. Gross profit was RMB 4.857 billion, with a gross margin of 34.1%. Profit for the year was RMB 1.062 billion, down 18.5%, while adjusted profit for the year was RMB 1.530 billion, up 1.3%. By segment, revenue from enterprise customers was RMB 11.344 billion and revenue from own-brand business was RMB 2.912 billion.
Mar.18 by 2FIRSTS.ai
STG UK refreshes XQS nicotine pouch packaging: new flavour indicators, hitting retail from March
STG UK refreshes XQS nicotine pouch packaging: new flavour indicators, hitting retail from March
Scandinavian Tobacco Group UK (STG UK) has announced a rebrand across its XQS nicotine pouch range. The updated packaging will be visible at retail from March, with the recommended retail price remaining £5.50. The new packs feature a bolder logo and glossy textures, retain nicotine strength indicators, and add a side flavour profile indicator to show the flavour type.
Feb.28 by 2FIRSTS.ai
FDA nicotine pouch review delay report knocks tobacco shares lower
FDA nicotine pouch review delay report knocks tobacco shares lower
After Reuters reported before the market open that FDA reviews of nicotine pouch applications could face delays, shares of Philip Morris International, Turning Point Brands and British American Tobacco fell on April 1, underscoring the direct impact of U.S. regulatory signals on major tobacco companies and nicotine pouch expectations.
Apr.02